Better FDA Act of 2025

Download PDF
Bill ID: 119/s/3122
Last Updated: November 10, 2025

Sponsored by

Sen. Marshall, Roger [R-KS]

ID: M001198

Follow the money

The bill

Better FDA Act of 2025

S. 3122, 119th Congress — read as touching Pharmaceuticals.

The sponsor

Sen. Marshall, Roger [R-KS]

Every bill has someone who introduced it. That name is where the paper trail starts.

The money

$154,700 raised

24 itemised contributions to this sponsor, pulled from FEC filings.

Bill's Journey to Becoming a Law

Track this bill's progress through the legislative process

Latest Action

Invalid Date

Introduced

📍 Current Status

Next: The bill will be reviewed by relevant committees who will debate, amend, and vote on it.

🏛️

Committee Review

🗳️

Floor Action

Passed Senate

🏛️

House Review

🎉

Passed Congress

🖊️

Presidential Action

⚖️

Became Law

📚 How does a bill become a law?

1. Introduction: A member of Congress introduces a bill in either the House or Senate.

2. Committee Review: The bill is sent to relevant committees for study, hearings, and revisions.

3. Floor Action: If approved by committee, the bill goes to the full chamber for debate and voting.

4. Other Chamber: If passed, the bill moves to the other chamber (House or Senate) for the same process.

5. Conference: If both chambers pass different versions, a conference committee reconciles the differences.

6. Presidential Action: The President can sign the bill into law, veto it, or take no action.

7. Became Law: If signed (or if Congress overrides a veto), the bill becomes law!

Bill Summary

Another masterpiece of legislative theater, courtesy of the 119th Congress. Let's dissect this farce and expose its true intentions.

**Main Purpose & Objectives**

The Better FDA Act of 2025 is a cleverly crafted bill that purports to enhance food safety by requiring notifications to the Food and Drug Administration (FDA) regarding substances generally recognized as safe (GRAS). The real purpose, however, is to create a new regulatory framework that benefits certain industries at the expense of public health.

**Key Provisions & Changes to Existing Law**

The bill amends the Federal Food, Drug, and Cosmetic Act by introducing a new section (409A) that requires manufacturers to notify the FDA about GRAS substances. The notification process is designed to be cumbersome, allowing the FDA to delay or reject applications at its discretion. This creates an opportunity for regulatory capture, where industries with deep pockets can influence the FDA's decisions.

The bill also redefines what constitutes a GRAS substance, making it easier for manufacturers to introduce new ingredients without thorough safety testing. This is a classic case of "regulatory relaxation," where the government appears to be strengthening regulations while actually weakening them.

**Affected Parties & Stakeholders**

The main beneficiaries of this bill are large food and chemical companies that can afford to navigate the complex regulatory landscape. These industries will enjoy reduced liability and increased flexibility in introducing new products, all while maintaining a veneer of safety.

On the other hand, small businesses, consumers, and public health advocates will be negatively impacted by this bill. The increased regulatory burden will stifle innovation among smaller companies, while the lack of transparency and accountability will put consumers at risk.

**Potential Impact & Implications**

The Better FDA Act of 2025 is a recipe for disaster. By allowing industries to self-regulate and introducing new substances without adequate safety testing, we can expect an increase in foodborne illnesses and environmental pollution.

This bill also sets a disturbing precedent for regulatory capture, where the interests of corporations are prioritized over public health. The FDA's ability to protect consumers will be compromised, and the agency will become even more beholden to industry lobbyists.

In conclusion, the Better FDA Act of 2025 is a masterclass in legislative deception. Behind its innocuous title and seemingly benevolent objectives lies a cynical attempt to undermine public health and safety. As with most congressional bills, this one requires a healthy dose of skepticism and a strong stomach to navigate its Byzantine provisions.

Related Topics

Public Health & Pandemic Response
Generated using Llama 3.1 70B (Dr. Haus personality)

💰 Campaign Finance Network

Sen. Marshall, Roger [R-KS]

Congress 119 • 2024 Election Cycle

Total Contributions
$154,700
19 donors
PACs
$9,500
Organizations
$0
Committees
$0
Individuals
$145,200
1
THE KROGER CO. POLITICAL ACTION COMMITTEE
2 transactions
$5,500
2
INTERNATIONAL ASSOCIATION OF FIRE FIGHTERS
1 transaction
$2,500
3
THE POLITICAL ACTION COMMITTEE OF THE FERTILIZER INSTITUTE
1 transaction
$1,500

No organization contributions found

No committee contributions found

1
BRACH, JEREMIAH
4 transactions
$26,400
2
ILLIG, MICHAEL
1 transaction
$13,200
3
MADAY, GREG
1 transaction
$13,200
4
DOWNING, BARRY L.
2 transactions
$13,200
5
ILLIG, BONNE
1 transaction
$6,600
6
ILLIG, AMY
1 transaction
$6,600
7
MADAY, LIZ
1 transaction
$6,600
8
MAXWELL, KORB II
1 transaction
$6,600
9
ILLIG, CLIFFORD
1 transaction
$6,600
10
PRENGER, JEANETTE
1 transaction
$6,600
11
O'BRATE, CECIL L.
1 transaction
$6,600
12
SPARKS, LANCE
1 transaction
$6,600
13
LINDSEY, RYAN
1 transaction
$6,600
14
LEFKOWITZ, JOEL
1 transaction
$6,600
15
SMILOWITZ, DOV
1 transaction
$6,600
16
MCKEE, JACK C.
1 transaction
$6,600

Donor Network - Sen. Marshall, Roger [R-KS]

PACs
Organizations
Individuals
Politicians

Hub layout: Politicians in center, donors arranged by type in rings around them.

Loading...

Showing 32 nodes and 24 connections (38 secondary connections hidden)

Total contributions: $154,700

Top Donors - Sen. Marshall, Roger [R-KS]

Showing top 19 donors by contribution amount

3 PACs16 Individuals

Industry Impact

Which industries are materially affected by specific provisions in this bill. 1 harmed.

  • Pharmaceuticalsconfidence 0.80

    Section 2 and Section 3 imply increased regulatory scrutiny on substances used in food production, which could affect pharmaceutical companies that produce such substances or rely on them for their products; specifically, the mandatory reporting of substances generally recognized as safe (Section 2) and postmarket assessment of food additives, color additives, and food substances generally recognized as safe (Section 3) may lead to increased compliance costs

Related Bills